Поражение печени при псориазе и псориатическом артрите: обзор литературы

Автор: Корсакова Ю.Л., Коротаева Т.В.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Обзоры

Статья в выпуске: 4 т.55, 2017 года.

Бесплатный доступ

Псориаз (Пс) является хроническим системным заболеванием, поражающим кожу. Исследования позволили выявить высокую распространенность неалкогольной жировой болезни печени (НАЖБП) у больных Пс по сравнению с общей популяцией, особенно у тех, кто страдает среднетяжелыми и тяжелыми формами Пс с высоким индексом распространенности и тяжести Пс (PASI). Определенную роль в этой взаимосвязи играют аналогичные патогенетические процессы. Среди наиболее вероятных причин выделяют резистентность к инсулину и повышение уровней провоспалительных цитокинов. По последним данным, распространенность НАЖБП и метаболического синдрома среди больных Пс выше, чем в популяции в целом. Кроме того, пациенты с НАЖБП и Пс имеют более высокий риск развития тяжелого фиброза печени, чем лица с НАЖБП и без Пс. Терапия этого состояния несомненно должна проводиться по пути не только модификации традиционных факторов риска, но и надежного подавления воспаления. Наличие ожирения и НАЖБП оказывает отрицательное влияние и на результаты лечения больных псориатическим артритом генно-инженерными биологическими препаратами.

Еще

Псориаз, псориатический артрит, неалкогольная жировая болезнь печени

Короткий адрес: https://readera.org/14945843

IDR: 14945843   |   DOI: 10.14412/1995-4484-2017-429-435

Список литературы Поражение печени при псориазе и псориатическом артрите: обзор литературы

  • Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96 DOI: 10.1038/jid.2010.103
  • Christophers E. Psoriasis -epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20 DOI: 10.1046/j.1365-2230.2001.00832.x
  • Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912 DOI: 10.1056/NEJMra041320
  • Ganzetti G, Campanati A, Scocco V, et al. The potential effect of the tumour necrosis factor-а inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94:715-7 DOI: 10.2340/00015555-1801
  • Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-8 DOI: 10.1016/j.clinderma-tol.2007.08.003
  • Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004;50:4 DOI: 10.1016/j.jaad.2003.11.046
  • Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermosifiliogr. 2010;101:657-8 DOI: 10.1016/j.ad.2010.06.004
  • Farley E, Menter A. Psoriasis: comorbidities and associations. Ital Dermatol Venereol. 2011;146:9-15.
  • Ramos AN, de Oliveira Rocha B, de Almeida Rego V, et al. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat. 2014;22(2):132-6.
  • Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968 DOI: 10.4414/smw.2014.13968
  • Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol. 2009;51:758-64 DOI: 10.1016/j.jhep.2009.04.020
  • Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol. 2014;33:95-9 DOI: 10.1016/j.repc.2013.06.017
  • Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012;11:s5-10.
  • Paschos P, Paleta K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9-19.
  • Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18:297-304.
  • Ludwig J, Viqgiano TR, McGill DB, et al. Nonalcoholic statohepatitis: Meyo Clinic experience with a hitherto unnamed disease. Meyo Clin Proc. 1980;55:434-8.
  • Farrel GC, Larter CZ. Non-alcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43:S99-S112 DOI: 10.1002/hep.20973
  • Полунина ТЕ, Маев ИВ. Неалкогольная жировая болезнь печени: эпидемиология, патогенез, диагностика, лечение. Consilium medicum. Гастроэнтерология. 2012;(1):35-40
  • Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-84 DOI: 10.1016/j.jhep.2010.04.008
  • European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402 DOI: 10.1016/j.jhep.2015.11.004
  • Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33 DOI: 10.1111/j.1464-5491.2005.01748.x
  • Bitencourt AGV, Cotrim HP, Alves E, et al. Doenca hepatica gordurosa nao alcoolica: caracteristicas clinicas e histologicas em obesos graves submetidos a cirurgia bariatrica. Acta Gastroenterol Latinoam. 2007;37:224-30.
  • Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38 DOI: 10.1161/ATVBAHA.107.147538
  • Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95 DOI: 10.1002/hep.20466
  • Karnikowiski M, Cordova C, Oliveira RJ, et al. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian median-aged and older adults. Sao Paulo Med J. 2007;125:333-7 DOI: 10.1590/S1516-31802007000600006
  • Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128-46 DOI: 10.1055/s-0031-1276643
  • Leonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis. 2001;33:86-7 .
  • Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54 DOI: 10.1002/hep.21496
  • Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-30 DOI: 10.1016/j.dld.2010.01.016
  • Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: A novel hepatodermal axis? Int J Mol Sci. 2016;17:217 DOI: 10.3390/ijms17020217
  • Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-86 DOI: 10.1016/j.jhep.2009.06.008
  • Madanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriaticpatients: A study from South India. Australas J Dermatol. 2012;53:190-7 DOI: 10.1111/j.1440-0960.2012.00905.x
  • Van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-24 DOI: 10.1016/j.jaad.2013.10.044
  • Van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A crosssectional analysis from the Rotterdam study. Acta Derm Venereol. 2016;96:213-7 DOI: 10.2340/00015555-2161
  • Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;30:282-7 DOI: 10.1111/jdv.13456
  • Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722-7 DOI: 10.1111/ced.12672
  • Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300 DOI: 10.1111/apt.13042
  • Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-62 DOI: 10.1111/jdv.12847
  • Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-66 DOI: 10.1016/S0899-9007(01)00672-4
  • Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56 DOI: 10.1210/jc.2004-0395
  • Campanati A, Ganzetti G, Marra M, et al. Serum levels of adipocytokines in psoriatic patients receiving TNF-alpha inhibitors: results of a retrospective analysis. Intern J Dermatol. 2015;54:839-45 DOI: 10.1111/ijd.12706
  • Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxford). 2006;64:355- DOI: 10.1111/j.1365-2265.2006.02474.x
  • Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30 DOI: 10.1016/j.cca.2007.01.026
  • Xu A, Wang Y, Keshaw H, et al. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100 DOI: 10.1172/JCI200317797
  • Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177-84 DOI: 10.1002/hep.20282
  • Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Metabolism. 2011;60:313-26 DOI: 10.1016/j.metabol.2010.09.003
  • Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92 DOI: 10.1172/JCI29126
  • Targher G, Bertolini L, Scala L, et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxford). 2004;61:700-3 DOI: 10.1111/j.1365-2265.2004.02151.x
  • Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016 May;68(5):1060-71 DOI: 10.1002/art.39573
  • Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. JEADV. 2010;24:P013.
  • Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-71 DOI: 10.1055/s-2008-1027411
  • Bhutani T, Hong J, Koo J. Contemporary diagnosis and management of psoriasis. 5th ed. Newtown, PA: Handbooks in Healthcare; 2011. P. 50-9.
  • Toussirot E, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol. 2014;5:368 DOI: 10.3389/fimmu.2014.00368
  • Di Minno MND, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-а blockers treatment: a prospective study. Arthritis Res Ther. 2012;14(5):R211 DOI: 10.1186/ar4049
  • Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor а blockers. Ann Rheum Dis. 2014;73:1157-62 DOI: 10.1136/annrheumdis-2012-202812
  • Di Minno MND, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease. Arthritis Care Res. 2013;65(1):141- DOI: 10.1002/acr.21711
  • Hojgaard P, Glintborg В, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-а inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191-9 DOI: 10.1093/rheumatology/kew326
Еще
Статья научная